Cullinan Oncology, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for CGEM, updated each market day.
CGEM AI Sentiment
AI sees no strong directional signal for Cullinan Oncology, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Cullinan Oncology, Inc. Common Stock
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
Sector
Exchange
Market Cap
$920,602,406
Cap Tier
Employees
109
Headquarters
CAMBRIDGE, MA
Listed Since
Jan. 8, 2021
CGEM Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
CGEM Volatility
Cullinan Oncology, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
